SolarCity Corp (SCTY)
The largest insider buy of the week comes from SolarCity’s director Elon Musk. Musk is also the CEO and brains behind Tesla Motors (TSLA). Over the past week Elon Musk and two others made very significant buys after the company announced a new acquisition.
The insiders all purchased their shares for $46.54 per share.
Director Elon Musk purchased a massive 214,869 shares. This cost the director a total of $10,000,003. The price is up 24.24% since then. Musk now holds on to over 21 million shares of the company’s stock.
CEO Lyndon Rive added 107,434 shares to his position in the company. These shares cost Rive a total transaction amount of $4,999,979. As of his most recent buy, Rive holds on to 2.839 million shares of his company’s stock.
Chief Revenue Officer Hayden Barnard also purchased 107,434 shares at $46.54 per share, costing him $4,999,979. This was the first buy for Barnard, so his total number of shares is 107,343.
These are the first insider transactions for the company since its IPO in 2012.
SolarCity is engaged in designing, sales, engineering, installation, monitoring, maintenance and financing of solar energy systems to residential and commercial customers, or sale of electricity generated by solar energy systems to customers.
SolarCity’s historical revenue and net income:
SolarCity recently announced that it would be acquiring Zep Solar. SolarCity will acquire Zep Solar for $158 million. The transaction is structured as an acquisition of all of the outstanding capital stock of Zep Solar through a merger of Zep Solar with a wholly-owned acquisition subsidiary of SolarCity.
SolarCity Corp has a market cap of $4.94 billion. Its shares are currently trading at around $58.67 with a P/S ratio of 22.50 and a P/B ratio of 25.10.
There are currently no guru shareholders of SolarCity.
EV Energy Partner LP (EVEP)
Over the past week there were two significant insider buys coming from corporate executives.
Executive Chairman of the Board John Walker purchased a very large 135,000 shares at an average price of $36.86 per share. This cost the Chairman a total of $4,976,100. Since his buy, the price per share is up about 0.79%. Walker now holds on to 1.95 million shares of company stock.
President and CEO Mark Houser purchased 15,000 shares at $36.86 per share. This cost the CEO a total of $552,900. Since his transaction the price per share is trading up about 0.79%. Houser now holds on to a total of 463,078 shares of EV Energy Partner stock.
EV Energy Partner LP is engaged in the acquisition, development and production of oil and natural gas properties.
EV Energy’s historical revenue and net income:
The company recently announced the acquisition of Barnett Shale. EVEP agreed to acquire a 31% interest in these assets for $67.6 million. This acquisition is set to close on Oct. 31, 2013.
The analysis on EV Energy reports that the company has issued $661.2 million of debt over the past three years, its dividend yield is at a 3-year high and its P/B and P/S ratios are near record lows.
EV Energy has a market cap of $1.58 billion. Its shares are currently trading at around $37.17 with a P/S ratio of 5.20 and a P/B ratio of 1.60. The company currently holds a dividend yield of 8.30%.
There have been three notable buys coming from KeyCorp over the past week. These three buys come from three different directors: Ruth Ann Gillis, Edward Campbell and Charles Cooly.
Gillis added 1,000 shares to her stake on Oct. 21 at an average price of $12.59 per share. This transaction cost her a total of $12,590. Since her buy, the price per share is up about 0.32%. Gillis now holds on to a total of 3,500 shares of company stock.
Campbell made the largest buy, adding 8,000 shares to his holdings. The director purchased these shares at $12.50 per share for a transaction amount of $100,000. Since his buy the price per share is up about 1.04%. Campbell now holds on to at least 14,812 shares of company stock.
Cooly bought 2,000 shares of company stock on Oct. 18. The director purchased these shares for $12.48 for a total transaction amount of $24,960. Since his buy the price per share has increased approximately 1.2%. Cooly now holds on to 3,000 shares of Key stock.
KeyCorp is a parent holding company for KeyBank National Association, its principal subsidiary, through which most of its banking services are provided. Through KeyBank the Company provides retail and commercial banking, commercial leasing, consumer finance and investment banking products and services to individual clients.
KeyCorp’s historical revenue and net income:
The analysis on KeyCorp reports that the company’s dividend yield is at a 1-year low, its revenue has been in decline over the past five years and its P/E and P/S ratios are trading at near record highs.
The company’s recently released third quarter financials reported:
· Net income of $229 million, or $0.25 per share, up from $193 million, or $0.21 per share.
· Loans up 5% from last year.
· Revenue decreased $53 million from last year.
· Net interest margin of 3.11%, down 12 basis points.
The company’s CEO Beth Mooney has been named the Most Powerful Woman in Banking by American Banker.
KeyCorp has a market cap of $11.56 billion. Its shares are currently trading at around $12.68 with a P/E ratio of 14.30, a P/S ratio of 2.80 and a P/B ratio of 1.20. The company currently offers a dividend yield of 1.70%.
Catalyst Pharmaceutical Partners (CPRX)
Over the past week three insiders made notable buys into the company’s stock. The insiders consisted of Director David Tierney, Director Charles O’Keeffe and President and CEO Patrick McEnany.
Tierney added 8,000 shares to his stake at an average price of $2.03 per share. This cost the director a total of $16,240. The price per share has dropped approximately -7.88% since his buy. Tierney now holds on to 213,401 shares of company stock.
O’Keeffe purchased 10,000 shares at an average price of $1.84 per share. This transaction cost him $18,400. Since his buy, the price per share has increased about 1.63%. O’Keeffe now holds on to at least 167,126 shares of company stock.
McEnany made the largest buy of the week, adding 50,000 shares to his holdings. He bought these shares at an average price of $1.59 per share for a total transaction amount of $79,500. Since his buy, the price per share is up about 17.61%.
These are the first insider transactions reported for the company since December 2012.
Catalyst Pharmaceutical is a development-stage specialty pharmaceutical Company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system with a focus on the treatment of neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome, infantile spasms and Tourette’s disorder.
Catalyst Pharmaceutical’s historical revenue and net income:
The analysis on Catalyst reports that the revenue has been in decline for the past three years and that the company currently holds no debt.
Catalyst recently announced that they would be proceeding on to Phase III of their clinical trial for their product, Firdapse, which is a medication for the treatment of Lambert-Eaton Myasthenic Syndrome.
Several law firms have recently announced that they are investigating Catalyst Pharmaceutical for potential securities fraud claims. They claim that Catalyst may have concealed that one of its competitors has been providing patients for free with a drug that is nearly biologically equivalent to the drug Catalyst is seeking FDA approval of.
Catalyst Pharmaceutical Partners has a market cap of $101.7 million. Its shares are currently trading at around $1.87 with a P/B ratio of 7.50.
You can check out the top insider buys by using the GuruFocus All-in-One Screener.
Try a free 7-day GuruFocus Global Membership here.